Spero Therapeutics (NASDAQ:SPRO) Price Target Raised to $6.00

Spero Therapeutics (NASDAQ:SPRO) had its target price increased by HC Wainwright from $5.00 to $6.00 in a research report sent to investors on Monday morning, Marketbeat reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Spero Therapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.88) EPS.

Separately, Weiss Ratings raised Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $6.00.

Spero Therapeutics Stock Performance

SPRO stock opened at $1.11 on Monday. The stock has a fifty day moving average of $1.30 and a 200-day moving average of $2.10. Spero Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.08. The company has a market capitalization of $64.65 million, a price-to-earnings ratio of 10.09 and a beta of 1.49.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. Equities analysts predict that Spero Therapeutics will post -0.58 EPS for the current year.

Hedge Funds Weigh In On Spero Therapeutics

A number of large investors have recently modified their holdings of the company. Susquehanna Fundamental Investments LLC purchased a new stake in Spero Therapeutics in the second quarter worth approximately $36,000. Global Retirement Partners LLC purchased a new position in shares of Spero Therapeutics during the second quarter worth approximately $55,000. Intrepid Family Office LLC raised its stake in shares of Spero Therapeutics by 50.0% during the fourth quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock worth $384,000 after acquiring an additional 55,000 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth approximately $632,000. Finally, BlackRock Inc. bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth approximately $1,314,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company develops therapies for serious bacterial infections and certain rare diseases, with a focus on addressing conditions for which existing treatment options are limited or inadequate.

Spero’s lead program is tebipenem pivoxil hydrobromide, an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections. The company’s pipeline has also included SPR720, an investigational oral therapy for nontuberculous mycobacterial pulmonary disease, and SPR206, an investigational intravenous antibiotic intended for use against serious hospital infections caused by drug-resistant bacteria.

Founded in 2013, Spero has advanced its programs through collaborations and development partnerships, including a former agreement with GlaxoSmithKline.